We’re #hiring a new Computational Biology Scientist in New York. Apply today or share this post with your network.
Envisagenics
生物技术研究
New York，NY 8,415 位关注者
Artificial Intelligence, High Performance Computing, and RNA sequencing data to find cures faster than ever before.
关于我们
Envisagenics was founded in 2014 as a spinout of Cold Spring Harbor Laboratory. Our mission is to reduce the complexity of biomedical data to accelerate the development of innovative therapeutic solutions through RNA splicing analytics and artificial intelligence. We focus on the discovery of RNA therapeutics. Over 30 million people in the US suffer from genetic diseases or cancer that could be caused by mutations affecting RNA splicing. 370 human diseases are known to be caused by splicing errors, and more remain to be discovered. Our breakthrough technology, SpliceCore, is a cloud-based platform that is experimentally validated to predict drug targets and biomarkers through splicing discovery from RNA-seq data, using Artificial Intelligence. We are using our software to identify splicing errors causative of diseases, identify the right drug-targets and develop RNA therapeutics through partnerships and collaborations with Biopharma. Our in-silico RNA therapeutics discovery platform replaces expensive drug-target selection and lead design with efficient computer simulations, decreasing time, cost, and failure risk of drug development programs.
- 网站
-
https://www.envisagenics.com/
Envisagenics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- New York，NY
- 类型
- 私人持股
- 创立
- 2014
- 领域
- Drug Discovery、Artificial Intelligence、Machine Learning、RNA、Splicing、AI和Deep Learning
地点
-
主要
获取路线
30-02 48th Ave
Ste. 140
US，NY，New York，11101
Envisagenics员工
动态
-
Envisagenics is thrilled to announce that our CEO, Maria Luisa Pineda, PhD., has been named an honoree of Inc. Magazine's 2025 #FemaleFounders500 (https://lnkd.in/ex4jJGAp)! This prestigious list recognizes the most inspiring women in business, and we couldn’t be prouder to see Maria Luisa Pineda, PhD.'s leadership and vision celebrated. Her dedication to advancing #AI-driven drug discovery and empowering innovation in #lifesciences continues to inspire us every day. Congratulations, Maria Luisa Pineda, PhD.! Read the full article here: https://lnkd.in/d_2CzDy #WomenInBio #AIinLifeSciences #HealthcareInnovation #Leadership #Envisagenics #AI #ML #ArtificialIntelligence #MachineLearning #LifeSciences?
-
-
On February 13th our CEO, Maria Luisa Pineda, PhD. joined an expert panel, hosted by MIT Sloan Alumni Club of New York and moderated by Stephanie Oestreich, Managing Director of Multiple Myeloma Research Foundation - MMRF to discuss how AI is transforming biotech, from early discovery to drug development. A huge thank you to MIT Sloan Alumni Club of New York for hosting with Kristopher Brown from Goodwin for this thought-provoking event! #AI #ML #ArtificialIntelligence #MachineLearning #LifeSciences #MIT #Biotech #RNAsplicing #MultipleMyeloma
-
-
Envisagenics is excited to welcome Sudhir Rao, MBA, M.S., as our new Chief Business Officer! Sudhir Rao brings extensive experience in biotech business development, strategic partnerships, and growth initiatives, with deep expertise in oncology, neurology, and immunology therapeutic areas. His leadership will be instrumental as we continue to advance our growing pipeline of promising AI-identified drug targets and novel therapeutics. Read the full press release here: https://rb.gy/d9rhi5 Join us in welcoming Sudhir Rao to the team! #Envisagenics #Biopharma #Biotech #AIinBiopharma #RNAtherapeutics
-
On February 10 at 4:00 PM, Envisagenics’ CEO, Maria Luisa Pineda, PhD., will join an expert panel at the BIO CEO & Investor Conference to dive into AI’s Utility in Pharmacokinetics and Biomarker Selection. ? The discussion will feature Deirdre De Steno PhD MBA (Owkin) and Michael Foley (Excelsior Sciences), and moderated by Ricardo Vilanova (EY). ? Join us for a deep dive into the cutting-edge of biotech innovation: https://lnkd.in/eB6H-5vE ? #BIOCEO2025 #AIinHealthcare #BiotechInnovation #Pharmacokinetics #BiomarkerDiscovery #DrugDiscovery
-
-
Today, on #WorldCancerDay, Envisagenics stand united with the global community to advance the fight against cancer. At Envisagenics, we are proud to contribute to this mission by using our SpliceCore platform to uncover novel therapeutic targets through RNA splicing analysis. Our commitment goes beyond innovation—it’s about creating real, tangible hope for patients, their families, and the healthcare providers working tirelessly to save lives. Let’s work together to create a future where cancer is no longer a formidable opponent. Join us in raising awareness and championing innovation. Together, we can make a difference. #AIinBiotech #CancerResearch #WorldCancerDay #InnovationForLife #SpliceCore #Oncology #HopeThroughScience
-
-
Join Us at Women In Bio New York Metro event on February 6, 2025. Maria Luisa Pineda, PhD., CEO & Co-founder of Envisagenics, will be part of an exciting panel discussion with Jessily R.(CureAI Insights) and?Logan Troppito?(Accenture) on AI's disruptive and exhilarating impact on the life sciences industry. Moderated by Dr. Glennis Mehra?(Biolabs@NYULangone), the conversation will explore the near-term status and future potential of AI in transforming life sciences—don't miss this chance to hear from industry leaders at the forefront of innovation. Register for the event here: https://lnkd.in/ef4sX6Nm #WomenInBio #AIinLifeSciences #HealthcareInnovation #Leadership #Envisagenics
-
-
We were honored to participate in this distinguished panel at JPM Week 2025, discussing the transformative role of AI in target/drug discovery and drive innovation. Thank you to Greg Meyers for providing an excellent recap of the key takeaways—be sure to read it for valuable insights. We look forward to advancing these important conversations and fostering meaningful collaborations in the year ahead. #OneBMS #JPM25 #AIinDrugDiscovery #DrugDevelopment #HealthcareInnovation #Biotech #InnovationInHealthcare #Envisagenics
EVP, Chief Digital & Technology Officer, Member of Executive Committee at Bristol Myers Squibb
Today, I posted some reflections on my time last week at the JP Morgan Healthcare Conference, the world's largest gathering of healthcare and life sciences companies to sum it up: "AI is Taking Center Stage".
-
Last week at #JPM2025, Maria Luisa Pineda, PhD., PhD, Co-founder and CEO of Envisagenics, moderated a thought-provoking panel in the Imperial Ballroom at Hilton San Francisco Union Square. The session brought together leading minds in the industry: Andrei Georgescu, Ph.D. (Vivodyne), Wyatt McDonnell (Infinimmune), Khai Minh Pham MD, PhD (AI), MD, PhD (AI) (ThinkingNode Life Science, Inc.), Kfir Schreiber (DeepCure), and Hannah Wastyk (Interface Biosciences). The discussion delved into how artificial intelligence, machine learning, and large language models (LLMs) are transforming therapeutic development—from target and drug discovery pipelines to streamlining clinical trials and navigating regulatory landscapes. Key takeaways included: ? The potential of AI/ML in uncovering novel targets and therapies faster and more cost-effectively. ? LLMs enabling smarter, data-driven decision-making at every stage of drug development. ? The importance of collaboration between AI innovators and pharma to drive meaningful change. ? Addressing challenges in regulatory adaptation for cutting-edge technologies. ? It’s clear AI is not just a tool but a paradigm shift in how we approach healthcare innovation. Thank you to all the panelists for sharing their expertise and vision for the future! ? #AI #MachineLearning #DrugDevelopment #Therapeutics #Envisagenics #Innovation ?
-
-
Envisagenics is proud to see our CEO and co-founder,Maria Luisa Pineda, PhD., representing us at #JPM2025 in a dynamic panel discussion moderated by Zoey Becker from Fierce Pharma! She joined Lars Fogh Iversen, Sreenu Prakash Sai Jasti, Alexandra Gon?alves, MD, MMSc, PhD, and Najat Khan, PhD, to explore the transformative power of AI and machine learning in biotech, MedTech, and pharma. Topics ranged from leveraging AI for better health outcomes and drug discovery to breaking down innovation barriers and fostering a culture that embraces AI in our industry. Thank you to Fierce Pharma for hosting this insightful session, and to the fellow panelists for an engaging dialogue on shaping the future of life sciences. Together, we're pushing the boundaries of what's possible in patient care. #JPMWeek #FierceJPMWeek #Biotechnology #LifeSciences #AIinHealthcare
On Day 2 of #JPM2025, I took part in a panel discussion moderated by Zoey Becker from Fierce Pharma, focusing on the transformative impact of AI and machine learning in the biotech, MedTech, and pharma industries. Thank you to the organizers for the opportunity and to my fellow panelists—Sai Jasti, Maria Luisa Pineda, PhD., Alexandra Gon?alves, MD, MMSc, PhD and Najat Khan, PhD —for an engaging conversation on the latest trends, challenges, and opportunities in AI-driven advancements. We explored critical topics such as improving health outcomes through AI, leveraging technology in drug discovery, overcoming barriers to innovation, and fostering a culture that embraces AI within the industry. The insights shared were invaluable and highlighted the potential of AI to revolutionize patient care. #JPMWeek #FierceJPMWeek #Biotechnology #LifeSciences
-